Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis

2012 ◽  
Vol 30 (14) ◽  
pp. 1608-1614 ◽  
Author(s):  
Veena Shankaran ◽  
Sanjay Jolly ◽  
David Blough ◽  
Scott D. Ramsey

PurposeCharacteristics that predispose patients to financial hardship during cancer treatment are poorly understood. We therefore conducted a population-based exploratory analysis of potential factors associated with financial hardship and treatment nonadherence during and following adjuvant chemotherapy for colon cancer.Patients and MethodsPatients diagnosed with stage III colon cancer between 2008 and 2010 were identified from a population-based cancer registry representing 13 counties in Washington state. Patients were asked to complete a comprehensive survey on treatment-related costs. Patients were considered to have experienced financial hardship if they accrued debt, sold or refinanced their home, borrowed money from friends or family, or experienced a 20% or greater decline in their annual income as a result of treatment-related expenses. Logistic regression analysis was used to investigate factors associated with financial hardship and treatment nonadherence.ResultsA total of 284 responses were obtained from 555 eligible patients (response rate, 51.2%). Nearly all patients in the final sample were insured during treatment. In this sample, 38% of patients reported one or more financial hardships as a result of treatment. The factors most closely associated with treatment-related financial hardship were younger age and lower annual household income. Younger age, lower income, and unemployment or disability (which occurred in most instances following diagnosis) were most closely associated with treatment nonadherence.ConclusionA significant proportion of patients undergoing adjuvant chemotherapy for stage III colon cancer may experience financial hardship, despite having health insurance coverage. Interventions to help at-risk patients early on during therapy may prevent long-term financial adverse effects.

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Peng Gao ◽  
Xuan-zhang Huang ◽  
Yong-xi Song ◽  
Jing-xu Sun ◽  
Xiao-wan Chen ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4014-4014 ◽  
Author(s):  
I. H. Zuckerman ◽  
A. J. Davidoff ◽  
E. Onukwugha ◽  
N. Pandya ◽  
J. F. Gardner ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4103-4103
Author(s):  
Mohsin Soleja ◽  
Suleyman Yasin Goksu ◽  
Nina Niu Sanford ◽  
Muhammad Shaalan Beg ◽  
Radhika Kainthla ◽  
...  

4103 Background: Prior studies have observed under-utilization of adjuvant chemotherapy (ACT) in stage III colon cancer. Our aims were to observe the rate of utilization of ACT in very healthy or “ideal candidates”, identify reasons for omission and socioeconomic factors associated with ACT use, and observe patient outcomes. Methods: We queried patients from the National Cancer Database (NCDB) with stage III colon cancer, age<65, and Charlson-Deyo score of 0 who underwent resection in the United States between 2004-2015. Patients who received ACT were compared to patients who had surgery only (SO). We used chi-square test for categorical variables, Kaplan-Meier and Cox regression method for survival analyses. Results: Out of 243,388 stage III colon cancer patients during the study time, a total of 49,046 patients met the specific criteria of “ideal candidate”. Out of these, 88.5% received ACT and 11.5% underwent SO. The primary reason for chemotherapy omission was: no reason given (54.2%), patient/guardian refusal (26.7%), physician recommended against (9.3%), patient died (3%), unknown (6.7%). Patients who received ACT were more likely to be female, non-Hispanic white, have a higher level of education, travel shorter distance for cancer treatment, have private insurance or higher income as compared to counterpart ( all p<.001). Patients who received ACT had significantly better overall survival (5-year survival rate 74% vs. 54%, p<.001). This persisted after multivariable Cox regression analysis [HR:0.48 (CI:0.45-0.50), p<.001]. Conclusions: We observed a high rate of utilization (88.5%) of ACT in patients with stage III colon cancer who were under age 65 and without comorbidities. However, the omission of chemotherapy in this population remains a problem, partially due to patient refusal. Socioeconomic factors associated with lower utilization were primarily related to insurance status (private vs non-private). Patients who received ACT had significantly improved survival as compared to SO group. [Table: see text]


PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0194415 ◽  
Author(s):  
Karen J. Ortiz-Ortiz ◽  
Guillermo Tortolero-Luna ◽  
Ruth Ríos-Motta ◽  
Alejandro Veintidós-Feliú ◽  
Robert Hunter-Mellado ◽  
...  

2016 ◽  
Vol 14 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Christopher M. Booth ◽  
Sulaiman Nanji ◽  
Xuejiao Wei ◽  
Yingwei Peng ◽  
James J. Biagi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document